Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03435939 · ClinicalTrials.gov registry record · Early Phase 1

Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240

A Early Phase 1 study of Cystic Fibrosis, sponsored by University of Kansas Medical Center.

Active
Registry status
Early Phase 1
Development phase
16
Enrollment target
1
Study location

NCT03435939 is a Early Phase 1 study of Cystic Fibrosis that is active but no longer recruiting, run by University of Kansas Medical Center. The registered enrollment target is 16 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03435939, a Early Phase 1 study of Cystic Fibrosis, is active but no longer recruiting, sponsored by University of Kansas Medical Center.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to execute a small clinical proof of concept trial: To examine the effects of losartan on mucociliary clearance (MCC) in patients not eligible for CFTR rescue therapies

Conditions Studied

Interventions

  • DRUG Losartan

Study Locations (1)

Kansas

  • University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2022-02-15
Est. Completion 2026-02-28
Phase Early Phase 1

Sponsor

University of Kansas Medical Center

408 total trials

What the Registry Record Tells You About NCT03435939

The ClinicalTrials.gov registry entry for NCT03435939 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (91% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Losartan is the first listed.

NCT03435939 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT03435939 about?

NCT03435939 is a clinical study titled "Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240". The goal of this study is to execute a small clinical proof of concept trial: To examine the effects of losartan on mucociliary clearance (MCC) in patients not eligible for CFTR rescue therapies

What is the current status of trial NCT03435939?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2022-02-15. Estimated completion is 2026-02-28.

What conditions does trial NCT03435939 study?

This clinical trial studies the following conditions: Cystic Fibrosis.

What interventions are being tested in trial NCT03435939?

The interventions under investigation include: Losartan (DRUG).

Who is sponsoring clinical trial NCT03435939?

This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03435939 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.